Literature DB >> 7744174

Cystic fibrosis sputum induces a secretory response from airway gland serous cells that can be prevented by neutrophil protease inhibitors.

A Schuster1, J V Fahy, I Ueki, J A Nadel.   

Abstract

High activities of the neutrophil proteases, elastase and cathepsin G, are found in the sputum of patients with cystic fibrosis (CF). Because both proteases have been shown to be potent secretagogues for airway submucosal glands, and because hypersecretion is a characteristic feature of CF, the objective of the present study was to examine whether there is secretagogue activity in CF sputum, and to determine the contribution of neutrophil proteases to the secretagogue activity. Confluent monolayers of cultured bovine tracheal serous cells were pulse-labelled with Na2(35)SO4, incubated with diluted CF sputum supernatants in the presence or absence of different protease inhibitors, and the subsequent release of the radio-labelled macromolecules was measured. CF sputum potently induced secretion concentration-dependently. Addition of the selective neutrophil elastase inhibitor ICI 200,355 inhibited the secretory response to CF sputum supernatant by 89%. Addition of a cathepsin G-inhibitor resulted in further inhibition of the secretory response. Addition of phosphoramidon, a drug known to inhibit Pseudomonas aeruginosa elastase, had no effect. We conclude that CF sputum potently stimulates airway submucosal gland cell secretion. These studies with protease inhibitors suggest that neutrophil proteases account substantially for the secretagogue activity present in CF sputum.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7744174     DOI: 10.1183/09031936.95.08010010

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

1.  SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition.

Authors:  J Cooley; M K Sontag; F J Accurso; E Remold-O'Donnell
Journal:  Eur Respir J       Date:  2010-09-03       Impact factor: 16.671

2.  Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome.

Authors:  A Bellocq; M Antoine; A Flahault; C Philippe; B Crestani; J F Bernaudin; C Mayaud; B Milleron; L Baud; J Cadranel
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

Review 3.  Association of rhinovirus infections with asthma.

Authors:  J E Gern; W W Busse
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

4.  Airway proteins involved in bacterial clearance susceptible to cathepsin G proteolysis.

Authors:  M M Farberman; K T Akers; J P Malone; P Erdman-Gilmore; R R Townsend; T Ferkol
Journal:  Eur Respir J       Date:  2009-08-13       Impact factor: 16.671

Review 5.  Host immune responses to rhinovirus: mechanisms in asthma.

Authors:  John T Kelly; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2008-10       Impact factor: 10.793

Review 6.  Cystic fibrosis in adults. From researcher to practitioner.

Authors:  G P Marelich; C E Cross
Journal:  West J Med       Date:  1996-04

7.  Linkage of neutrophil serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory lung disease.

Authors:  F Rubio; J Cooley; F J Accurso; E Remold-O'Donnell
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139

Review 8.  The protease-antiprotease battle in the cystic fibrosis lung.

Authors:  I M Balfour-Lynn
Journal:  J R Soc Med       Date:  1999       Impact factor: 18.000

Review 9.  Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document.

Authors:  N G Papadopoulos; P Xepapadaki; P Mallia; G Brusselle; J-B Watelet; M Xatzipsalti; G Foteinos; C M van Drunen; W J Fokkens; C D'Ambrosio; S Bonini; A Bossios; Jan Lötvall; P van Cauwenberge; S T Holgate; G W Canonica; A Szczeklik; G Rohde; J Kimpen; A Pitkäranta; M Mäkelä; P Chanez; J Ring; S L Johnston
Journal:  Allergy       Date:  2007-02-27       Impact factor: 13.146

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.